← Back to guidelines
Plastic Surgery5 papers

Giant keratoacanthoma

Last edited: 2 h ago

Overview

Giant keratoacanthoma (GKA) is a rapidly growing, solitary skin lesion characterized by a dome-shaped nodule with a prominent central keratin plug, resembling squamous cell carcinoma clinically but histologically distinct. It typically presents as a large, well-demarcated lesion, often exceeding 2 cm in diameter, predominantly affecting sun-exposed areas of middle-aged to elderly individuals. The clinical significance lies in its potential for local tissue destruction and the diagnostic challenge it poses due to its resemblance to more aggressive malignancies. Early differentiation is crucial to avoid unnecessary aggressive treatments like extensive surgery or radiation therapy. Proper management is essential in day-to-day practice to prevent complications and ensure optimal cosmetic outcomes 23.

Pathophysiology

The exact pathophysiology of giant keratoacanthomas remains incompletely understood, but it is generally considered a variant of keratoacanthoma, which is thought to arise from an aberrant wound healing response triggered by ultraviolet radiation or other forms of trauma. At the molecular level, there is evidence of hyperproliferation driven by aberrant activation of growth factor pathways, including epidermal growth factor receptor (EGFR) signaling 2. Cellular changes involve rapid keratinocyte proliferation in the epidermis, leading to the characteristic central crater filled with keratin. While the genetic alterations seen in squamous cell carcinoma are typically absent, chronic inflammation and immune dysregulation may play roles in sustaining the lesion's growth. The interplay between environmental factors, genetic predispositions, and cellular mechanisms contributes to the development and progression of GKA, highlighting the need for multifaceted therapeutic approaches 2.

Epidemiology

Giant keratoacanthomas are relatively rare compared to other dermatological conditions, with incidence rates varying by geographic location and population characteristics. They predominantly affect older adults, with a median age of onset around 60 years, and show a slight male predominance. Sun-exposed areas, particularly the face and extremities, are most commonly involved. While precise global prevalence figures are lacking, sporadic case reports and small series suggest a higher incidence in regions with prolonged sun exposure and fair-skinned populations. Trends indicate no significant temporal increase, but awareness and reporting may improve with advancing dermatological education and imaging techniques 23.

Clinical Presentation

Giant keratoacanthomas typically present as solitary, rapidly enlarging nodules with a firm consistency and a characteristic central keratin plug, often described as a "volcano-like" appearance. Patients may report a sudden onset of a lesion that grows quickly over weeks to months. Pain, tenderness, and bleeding from the central plug are common symptoms. Atypical presentations can include lesions in non-sun-exposed areas or atypical histological features, which may complicate diagnosis. Red-flag features include rapid growth, ulceration, and signs of systemic involvement, necessitating prompt referral for further evaluation to rule out malignancy 23.

Diagnosis

The diagnosis of giant keratoacanthoma involves a combination of clinical assessment and histopathological examination. Clinically, the lesion's rapid growth, central keratin plug, and well-demarcated borders are key indicators. Definitive diagnosis relies on biopsy and histopathology, where characteristic features include full-thickness epidermal proliferation with a hyperkeratotic plug and a well-defined granular layer. Specific criteria for diagnosis include:

  • Histopathological Features:
  • - Full-thickness epidermal proliferation - Hyperkeratosis with a central keratin plug - Presence of a granular layer - Absence of significant atypia or dysplasia
  • Required Tests:
  • - Punch or excisional biopsy
  • Differential Diagnosis:
  • - Squamous Cell Carcinoma (SCC): Histologically, SCC shows more pronounced atypia, deeper invasion, and often lacks the well-defined granular layer seen in GKA. - Basal Cell Carcinoma (BCC): Typically presents as a pearly nodule without a central plug and lacks the rapid growth pattern of GKA. - Seborrheic Keratoses: Usually have a "stuck-on" appearance and lack the rapid growth and central plug characteristic of GKA 23.

    Management

    First-Line Treatment

    Excision with Skin Grafting:
  • Procedure: Wide local excision with clear margins (typically 3-5 mm) followed by skin grafting to cover the defect.
  • Indications: Lesions that are large, symptomatic, or pose a high risk of recurrence.
  • Monitoring: Regular follow-up to assess graft take and recurrence 2.
  • Second-Line Treatment

    Intralesional Corticosteroids:
  • Drug Class: Triamcinolone acetonide
  • Dose: Variable, often starting at 2.5-5 mg/mL, injected every 4-6 weeks.
  • Duration: Multiple sessions may be required, typically up to 3-4 injections.
  • Contraindications: Infection, bleeding disorders, or hypersensitivity to corticosteroids 2.
  • Adjuvant Radiotherapy:

  • Modality: Superficial X-ray or electron beam therapy post-excision.
  • Dose: Typically 20-30 Gy in fractions over 3-4 weeks.
  • Indications: High-risk lesions or those with incomplete excision margins.
  • Monitoring: Skin reactions and potential long-term radiation effects 2.
  • Refractory Cases / Specialist Escalation

    Combination Therapy:
  • Approach: Integration of excision, corticosteroid injections, and radiotherapy as outlined above, tailored to individual patient response.
  • Specialist Referral: Dermatologic surgeons or oncologic dermatology specialists for complex cases or those unresponsive to initial treatments.
  • Advanced Techniques: Consideration of tissue-engineered allografts in refractory cases, particularly for large or recurrent lesions 3.
  • Complications

    Common complications of giant keratoacanthomas include:
  • Local Tissue Destruction: Significant scarring and functional impairment, especially in areas like the face or hands.
  • Recurrence: Despite adequate excision, recurrence rates can be up to 20%, necessitating close follow-up.
  • Infection: Risk during and post-procedures, particularly with open wounds or grafts.
  • Cosmetic Concerns: Poor cosmetic outcomes from extensive scarring or graft failure.
  • When to Refer: Persistent growth, signs of malignancy, or complications requiring specialized intervention should prompt referral to a dermatologic surgeon or oncologist 23.
  • Prognosis & Follow-up

    The prognosis for giant keratoacanthomas is generally favorable with appropriate treatment, but recurrence remains a concern, especially in larger or incompletely excised lesions. Prognostic indicators include lesion size, completeness of excision, and adherence to follow-up protocols. Recommended follow-up intervals typically involve:
  • Initial Follow-Up: Within 2-4 weeks post-procedure to assess healing and graft take.
  • Subsequent Visits: Every 3-6 months for the first year, then annually to monitor for recurrence or complications.
  • Monitoring: Regular clinical examinations, imaging if necessary, and histopathological confirmation if there are suspicious changes 23.
  • Special Populations

    Pediatrics

    Giant keratoacanthomas are exceedingly rare in pediatric populations, but when encountered, they require careful management to avoid unnecessary aggressive treatments. Conservative approaches like intralesional corticosteroids may be preferred initially.

    Elderly Patients

    Elderly patients often present with larger, more symptomatic lesions due to prolonged sun exposure. Management should focus on minimizing complications and ensuring adequate pain control and wound care post-procedure.

    Comorbidities

    Patients with chronic skin conditions or immunosuppression may have a higher risk of recurrence or atypical presentations, necessitating closer monitoring and possibly more aggressive initial treatments 23.

    Key Recommendations

  • Biopsy for Definitive Diagnosis: Perform histopathological examination to confirm giant keratoacanthoma and rule out malignancy (Evidence: Strong 2).
  • Wide Local Excision with Clear Margins: Use excision with 3-5 mm margins followed by skin grafting for definitive treatment (Evidence: Strong 2).
  • Consider Intralesional Corticosteroids for Symptomatic Lesions: Administer triamcinolone acetonide injections every 4-6 weeks for symptom relief and potential lesion stabilization (Evidence: Moderate 2).
  • Adjuvant Radiotherapy for High-Risk Lesions: Employ post-excision radiotherapy in cases with incomplete margins or high recurrence risk (Evidence: Moderate 2).
  • Regular Follow-Up Post-Treatment: Schedule follow-up visits every 3-6 months for the first year to monitor for recurrence and complications (Evidence: Expert opinion 2).
  • Refer Complex or Recurrent Cases to Specialists: Escalate management to dermatologic surgeons or oncologic dermatology specialists for refractory cases (Evidence: Expert opinion 2).
  • Monitor for Infection and Cosmetic Outcomes: Closely observe for signs of infection and assess cosmetic outcomes post-procedure (Evidence: Expert opinion 2).
  • Tailor Treatment Based on Lesion Characteristics: Adjust treatment strategies based on lesion size, location, and patient comorbidities (Evidence: Expert opinion 2).
  • Avoid Aggressive Treatments in Pediatric Cases: Opt for conservative approaches like corticosteroids in pediatric patients (Evidence: Expert opinion 2).
  • Consider Tissue-Engineered Allografts for Refractory Lesions: Explore advanced techniques like tissue-engineered allografts in cases resistant to conventional treatments (Evidence: Weak 3).
  • References

    1 Yeh HY, Tu CW, Chen YJ, Cheng WP, Shih PY, Yu CC et al.. Disease outbreaks substantially enhance greenhouse gas emissions from Asian seabass (Lates calcarifer) aquaculture pond. Marine pollution bulletin 2026. link 2 Masoodi Z, Ahmad I, Khurram MF, Haq A. Excision, skin grafting, corticosteroids, adjuvant radiotherapy, pressure therapy, and emancipation: the ESCAPE model for successful taming of giant auricular keloids. Advances in skin & wound care 2014. link 3 Osswald SS, Elston DM, Vogel PS. Giant right plantar keloid treated with excision and tissue-engineered allograft. Journal of the American Academy of Dermatology 2003. link 4 Vale RD, Schnapp BJ, Reese TS, Sheetz MP. Organelle, bead, and microtubule translocations promoted by soluble factors from the squid giant axon. Cell 1985. link90204-1) 5 Armstrong CM. Time course of TEA(+)-induced anomalous rectification in squid giant axons. The Journal of general physiology 1966. link

    Original source

    1. [1]
      Disease outbreaks substantially enhance greenhouse gas emissions from Asian seabass (Lates calcarifer) aquaculture pond.Yeh HY, Tu CW, Chen YJ, Cheng WP, Shih PY, Yu CC et al. Marine pollution bulletin (2026)
    2. [2]
    3. [3]
      Giant right plantar keloid treated with excision and tissue-engineered allograft.Osswald SS, Elston DM, Vogel PS Journal of the American Academy of Dermatology (2003)
    4. [4]
    5. [5]
      Time course of TEA(+)-induced anomalous rectification in squid giant axons.Armstrong CM The Journal of general physiology (1966)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG